Interim Analysis of the Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia
John Mascarenhas(Tisch Hospital), Robert S. Hoffman(New York City Department of Health and Mental Hygiene), Giuseppe Prosperini(Mario Negri Sud Foundation), Alessandra Di Lelio(Mario Negri Sud Foundation), Murat O. Arcasoy(Duke University), Adam J. Mead(National Institute for Health and Care Research), Damiano Rondelli(University of Illinois Chicago), Mohamed E. Salama(The University of Texas at San Antonio Health Science Center), Lorenzo Marfisi(Mario Negri Institute for Pharmacological Research), Craig M. Kessler(Georgetown University), Heidi Kosiorek(Mayo Clinic in Florida), Ruben A. Mesa(Atrium Health Wake Forest Baptist), Rosalind Catchatorian(Stanger Hospital), Richard T. Silver(Cornell University), Josef T. Prchal(Huntsman Cancer Institute), Alessandro M. Vannucchi(Azienda Ospedaliero-Universitaria Careggi), Claire Harrison(Guy's and St Thomas' NHS Foundation Trust), Rona Singer Weinberg(University of North Carolina at Chapel Hill), Casey L. O’Connell(University of Southern California), Richard F. Schlenk(German Cancer Research Center), Valerio De Stefano(Agostino Gemelli University Polyclinic), Alessandro Rambaldi(Ospedale Papa Giovanni XXIII), Arnon Nagler(Sheba Medical Center), Marina Kremyanskaya(Tisch Cancer Institute), D Leibowitz(Sutter Health), Jill Kleczko(Tisch Hospital), Tiziano Barbui(University of Bergamo), Abdulraheem Yacoub(The University of Kansas Cancer Center), Mary Frances McMullin(Queen's University Belfast), Ellen K. Ritchie(Cornell University), Amylou C. Dueck(Mayo Clinic in Arizona), Gianni Tognoni(Fondazione Lelio e Lisli Basso), Joanne Ewing(Heart of England NHS Foundation Trust), Elliott F. Winton(Emory University), Eliseo Serone(University of L'Aquila), Dmitriy Berenzon(Atrium Health Wake Forest Baptist), Jean‐Jacques Kiladjian(Délégation Paris 5)
Cited by 28
Related Papers
Genomic Classification and Prognosis in Acute Myeloid Leukemia
|New England Journal of Medicine|2016|4.4k
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial
|Journal of Clinical Oncology|2015|2.6k